RNA Q3 2024 Earnings — Avidity Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RNAAvidity Biosciences, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-17.1% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$98M-4200.9% margin

Net Income

-$80M-3441.7% margin

EPS (Diluted)

$-0.65

QoQ Revenue Growth

+14.2%

Cash Flow

Operating Cash Flow

-$66M

Free Cash Flow

-$67M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$137M

Stockholders' Equity

$1.5B

Cash & Equivalents

$370M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-17.1%
Gross Profit	$2M	-$45M	+105.2%
Operating Income	-$98M	-$59M	-67.4%
Net Income	-$80M	-$52M	-53.6%